Novel lenalidomide-based combinations for treatment of multiple myeloma

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 1, 2013, Pages 9-20

  Cives, Mauro ^a   Simone, Valeria ^a   Brunetti, Oronzo ^a   Longo, Vito ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Bone resorption; Combination therapies; IMiDs; Lenalidomide; Multiple myeloma; New drugs

Indexed keywords

AURORA KINASE INHIBITOR; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; CARFILZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR; DACETUZUMAB; DELANZOMIB; DEXAMETHASONE; ELOTUZUMAB; EVEROLIMUS; IXAZOMIB; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANOBINOSTAT; PAZOPANIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLO LIKE KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; ROMIDEPSIN; SALINOSPORAMIDE A; SORAFENIB; SUNITINIB; TANESPIMYCIN; THALIDOMIDE; TUBACIN; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MULTIPLE MYELOMA; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84870800589     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.06.008     Document Type: Review

References (89)

1. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5):2516-2520.
2. Kristinsson S.Y., Landgren O., Dickman P.W., Derolf A.R., Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. Journal of Clinical Oncology 2007, 25(15):1993-1999.
3. San Miguel J.F. Relapse/refractory myeloma patients: potential treatment guidelines. Journal of Clinical Oncology 2009, 27(34):5676-5677.
4. Dalgleish A., Galustian C. The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncology 2010, 6(9):1479-1484.
5. Cives M., Milano A., Dammacco F., Silvestris F. Lenalidomide in multiple myeloma: current experimental and clinical data. European Journal of Haematology 2012, 88(4):279-291.
6. Palumbo A., Anderson K. Multiple myeloma. New England Journal of Medicine 2011, 364:1046-1060.
7. Quach H., Ritchie D., Stewart A.K., et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia 2010, 24:22-32.
8. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98(1):210-216.
9. Corral L.G., Haslett P.A., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology 1999, 163:380-386.
10. Corral L.G., Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Annals of the Rheumatic Diseases 1999, 58(Suppl. 1):1107-1113.
11. Dredge K., Marriott J.B., Todryk S.M., et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. Journal of Immunology 2002, 168(10):4914-4919.
12. LeBlanc R., Hideshima T., Catley L.P., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103(5):1787-1790.
13. Schafer P.H., Gandhi A.K., Loveland M.A., et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. Journal of Pharmacology and Experimental Therapeutics 2003, 305(3):1222-1232.
14. Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine 1998, 187:1885-1892.
15. Wu L., Adams M., Carter T., et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clinical Cancer Research 2008, 14:4650-4657.
16. Hayashi T., Hideshima T., Akiyama M., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology 2005, 128:192-203.
17. Zhu D., Corral L.G., Fleming Y.W., Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunology, Immunotherapy 2008, 57(12):1849-1859.
18. Benson D.M., Bakan C.E., Zhang S., et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer versus multiple myeloma effect. Blood 2011, 118(24):6387-6391.
19. Benson D.M., Bakan C.E., Mishra A., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal antibody anti-PD-1 antibody. Blood 2010, 116(13):2286-2294.
20. Galustian C., Meyer B., Labarthe M.C., et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy 2009, 58(7):1033-1045.
21. Prabhala R.H., Neri P., Bae J.E., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006, 107(1):301-304.
22. Feyler S., von Lilienfeld-Toal M., Jarmin S., et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-) alphabeta TCR (+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology 2009, 144(5):686-695.
23. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
24. Hideshima T., Chauhan D., Schlossman R., Richardson P., Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20(33):4519-4527.
25. Payvandi F., Wu L., Haley M., et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cellular Immunology 2004, 230(2):81-88.
26. Bernard M.P., Bancos S., Sime P.J., Phipps R.P. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Current Pharmaceutical Design 2008, 14(21):2051-2060.
27. Prince H.M., Mileshkin L., Roberts A., et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clinical Cancer Research 2005, 11(15):5504-5514.
28. Teo S.K. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS Journal 2005, 7(1):E14-E19.
29. Dredge K., Marriott J.B., Macdonald C.D., et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer 2002, 87(10):1166-1172.
30. De Luisi A., Ferrucci A., Coluccia A.M.L., et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clinical Cancer Research 2011, 17(7):1935-1946.
31. Dredge K., Horsfall R., Robinson S.P., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research 2005, 69(1-2):56-63.
32. Shadduck R.K., Latsko J.M., Rossetti J.M., Haq B., Abdulhaq H. Recent advances in myelodysplastic syndromes. Experimental Hematology 2007, 35:137-143.
33. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96(9):2943-2950.
34. Lentzsch S., LeBlanc R., Podar K., et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003, 17(1):41-44.
35. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99(12):4524-4530.
36. Anderson K.C. Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Seminars in Hematology 2005, 42:S3-S8.
37. Gandhi A.K., Kang J., Capone L., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Current Cancer Drug Targets 2010, 10(2):155-167.
38. Escoubet-Lozach L., Lin I.L., Jensen-Pergakes K., et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Research 2009, 69(18):7347-7356.
39. Breitkreutz I., Raab M.S., Vallet S., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22(10):1925-1932.
40. Anderson G., Gries M., Kurihara N., et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006, 107:3098-3105.
41. Silvestris F., Ciavarella S., De Matteo M., Tucci M., Dammacco F. Bone resorbing cells in multiple myeloma: osteoclasts myeloma cell polykaryons, or both?. Oncologist 2009, 14(3):264-275.
42. Roodman G.D. Mechanisms of bone metastasis. New England Journal of Medicine 2004, 350:1655-1664.
43. Kupisiewicz K. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention. Danish Medical Bulletin 2011, 58(5):B4277.
44. Morgan G. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Blood Reviews 2010, 24(S1):27-32.
45. Richardson P.G., Lonial S., Jakubowiak A.J., Harousseau J.L., Anderson K.C. Monoclonal antibodies in the treatment of multiple myeloma. British Journal of Haematology 2011, 154(6):745-754.
46. Hsi E.D., Steinle R., Balasa B., et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research 2008, 14(9):2775-2784.
47. Tai Y.T., Soydan E., Song W., et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009, 113(18):4309-4318.
48. Tai Y.T., Dillon M., Song W., et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008, 112(4):1329-1337.
49. Lonial S., Vij R., Harousseau J.L., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of Clinical Oncology 2012, [E-pub ahead of print].
50. Richardson P., Moreau P., Jakubowiak A., et al. Phase 2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Haematologica 2011, 96(S1):S106.
51. Agura E., Niesvizky R., Matous J., et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase Ib study. Blood 2009, 114:2870.
52. van der Veer M.S., de Weers M., van Kessel B., et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011, 96(2):284-290.
53. Benson D., Bakan C., Hofmeister C., et al. A phase I trial of IPH-2101, a novel anti-inhibitory KIR antibody, in patients with multiple myeloma. Haematologica 2011, 96(S1):S87.
54. Inoges S., de Cerio A.L., Soria E., Villanueva H., Pastor F., Bendandi M. Idiotype vaccines for human B-cell malignancies. Current Pharmaceutical Design 2010, 16(3):300-307.
55. Atanackovic D., Hildebrandt Y., Jadczak A., et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010, 95(5):785-793.
56. Anderson K.C. New insights into therapeutic targets in myeloma. Hematology/American Society of Hematology. Education Program 2011, 2011:184-190.
57. Luptakova K., Glotzbecker B., Mills H., et al. Lenalidomide decreases PD-1 expression, depletes regulatory T-cells and improves cellular response to a multiple myeloma/dendritic cell fusion vaccine in vitro. Blood 2010, 116:492.
58. Raschko M., Markovina S., Miyamoto S., et al. Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM). Blood 2007, 110:1173.
59. Callander N.S., Markovina S., Juckett M.B., et al. The addition of bevacizumab (B) to lenalidomide and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma (NCI#7317). Blood 2009, 114:3885.
60. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine 2007, 357(21):2133-2142.
61. Fan F., Schimming A., Jaeger D., Podar K. Targeting the tumor microenvironment: focus on angiogenesis. Journal of Oncology 2012, 2012:281261.
62. Richardson P.G., Weller E., Jagannath S., et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. Journal of Clinical Oncology 2009, 27(34):5713-5719.
63. Dimopoulos M.A., Kastritis E., Christoulas D., et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010, 24(10):1769-1778.
64. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116(5):679-686.
65. Niesvizky R., Bensinger W., Martin T., et al. Phase 1b/2 dose-ranging study of carfilzomib (cfz) in combination with lenalidomide (len) and dexamethasone (lodex) in relapsed-refractory multiple myeloma (R/R MM). Haematologica 2011, 96(S1):S91.
66. ®), and low dose dexamethasone is highly active in newly diagnosed multiple myeloma (MM): phase I/II MMRC study. Haematologica 2011, 96(S1):S106.
67. Foltankova V., Legartova S., Kozubek S., Bartova E. Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells. Neoplasma 2012, 59(4):450-462.
68. Ocio E.M., San Miguel J.F. The DAC system and associations with multiple myeloma. Investigational New Drugs 2010, 28(S1):S28-S35.
69. Ocio E.M., Vilanova D., Atadja P., et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010, 95(5):794-803.
70. Mateos M., Spencer A., Taylor K., et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or rel and refractory (Ref) multiple myeloma (MM). Journal of Clinical Oncology 2010, 28(15S):8030.
71. Richardson P.G., Weber D.M., Mitsiades C.S., et al. Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). Journal of Clinical Oncology 2010, 28(15S):8031.
72. Scherman E., Malak S., Perot C., Gorin N.C., Rubio M.T., Isnard F. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype. Leukemia 2012, 26(4):822-824.
73. Sekeres M.A., O'Keefe C., List A.F., et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. American Journal of Hematology 2011, 86(1):102-103.
74. Younes A., Samad N. Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011, 16(6):730-741.
75. Raje N., Kumar S., Hideshima T., et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004, 104(13):4188-4193.
76. Mahindra A.K., Richardson P.G., Hari P., et al. Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology 2010, 15S:8032.
77. Hofmeister C.C., Yang X., Pichiorri F., et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. Journal of Clinical Oncology 2011, 29(25):3427-3434.
78. Chen N., Kassera C., Kumar G., Palmisano M. Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein. Journal of Clinical Oncology 2012, 30(3):340-341.
79. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107(10):4053-4062.
80. David E., Sinha R., Chen J., Sun S.Y., Kaufman J.L., Lonial S. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clinical Cancer Research 2008, 14(16):5090-5098.
81. Jakubowiak A., Zimmerman T., Alsina M., et al. A multiple myeloma research consortium (MMRC) multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM): updated results. Blood 2007, 110:1169.
82. Jakubowiak A.J., Richardson P.G., Zimmermen T.D., et al. Final phase I results of perifosine in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Blood 2010, 116:3064.
83. Vitale I., Galluzzi L., Castedo M., Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nature Reviews. Molecular Cell Biology 2011, 12(6):385-392.
84. Hsu A.K., Quach H., Tai T., et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117(5):1605-1613.
85. Gandhi A.K., Kang J., Capone L., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor cell growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Current Cancer Drug Targets 2010, 10(2):155-167.
86. Mitsiades C.S. How " immunomodulatory" are IMiDs?. Blood 2011, 117(5):1440-1441.
87. Bladè J., Cibeira M.T., Rosiñol L. Novel drugs for the treatment of multiple myeloma. Haematologica 2010, 95(5):702-704.
88. Badros A.Z. Lenalidomide in myeloma - a high-maintenance friend. New England Journal of Medicine 2012, 366(19):1836-1838.
89. Dimopoulos M.A., Chen C., Spencer A., et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23(11):2147-2152.